| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6126920 | MYLAN | Method of treating a skin disease with a corticosteroid-containing pharmaceutical composition |
Mar, 2016
(8 years ago) | |
Olux is owned by Mylan.
Olux contains Clobetasol Propionate.
Olux has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Olux are:
- US6126920
Olux was authorised for market use on 26 May, 2000.
Olux is available in aerosol, foam;topical dosage forms.
Olux can be used as method of treating a skin disease with a corticosteroid-containing pharmaceutical composition.
The generics of Olux are possible to be released after 01 March, 2016.
Drugs and Companies using CLOBETASOL PROPIONATE ingredient
Market Authorisation Date: 26 May, 2000
Treatment: Method of treating a skin disease with a corticosteroid-containing pharmaceutical composition
Dosage: AEROSOL, FOAM;TOPICAL
How can I launch a generic of OLUX before it's drug patent expiration?
More Information on Dosage
OLUX family patents
